Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application. The following amendments do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Applicant reserves the right to pursue the subject matter of the canceled claims in this or any other appropriate patent application.

Listing of Claims:

- 1. (Currently Amended) A composition comprising between about 20 to about 26% Brassica oleracea 22.95±11%, between about 30 to about 36% Daucus carota 32.78±15%, between about 22 to about 28 % Apium graveolens L. 24.59±12%, between about 0.1 to about 1.5% Petroselinum crispum <1±0.5%, between about 9 to about 15% Spinacia oleracea L 11.47±5%, between about 6 to about 12% Beta vulgaris 8.19±4%, between about 0.1 to about 1.5% aloe vera <1±0.5%, and between about 0.1 to 1.5% honey <1±0.5%.
 - 2. Canceled.
 - 3. Canceled.
 - 4. Canceled.
 - 5. Canceled.
 - 6. Canceled.
- 7. (Currently amended) A dietary supplement comprising an effective amount of a composition of Cclaim 1.
- 8. (Currently amended) The composition of any of Cclaims 1-7 1, wherein the form of the composition is selected from the group consisting of an orally administered form, and an injectable form, and an externally applicable form.
- 9. (Currently amended) The composition of Cclaim 8, wherein the composition is in the orally administered form and the orally administrable form is selected from a group consisting of a

juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup, and a limonade.

10. (Currently amended) The composition of Cclaim 8, wherein the composition is in the injectable form and the injectable form is selected from the group consisting of a liquid, a suspension, and a solution.

11. Canceled.

- 12. (Currently amended) The A pharmaceutical composition comprising a pharmaceutically effective amount of a the composition of claim 1 and a pharmaceutically acceptable carrier.
- 13. (Currently amended) The pharmaceutical composition of Cclaim 12 7, wherein the form of the composition is selected from a group consisting of an orally administered form, and an injectable form, and an externally applicable form.
- 14. (Currently amended) The pharmaceutical composition of Eclaim 13, wherein the composition is in the orally administered form and the orally administrable form is selected from a group consisting of a juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup, and a limonade.
- 15. (Currently amended) The pharmaceutical composition of Cclaim 13, wherein the composition is in the injectable form and the injectable form is selected from the group consisting of a liquid, a suspension, and a solution.

16. Canceled.

- 17. (Currently amended) The composition of any of Cclaims 1-6 1, wherein the composition is administered as a dietary supplement to facilitate normal physiologic function and growth.
- 18. (Currently amended) The A method of administering the composition of any of Claims

 1 6, when taken at an effective dose claim 1, wherein the composition is administered over a period of time, reduces or eliminate tumor burden in to a patient having liver cancer.

- 19. (Currently amended) The A method of administering the composition of any of Claims

 1 6, when taken at an effective dose claim 1, wherein the composition is administered over a period of time, aids and expedites to a patient and the liver regenerationes.
- 20. (Currently amended) The A method of administering the composition of any of Claims 1—6, when taken at an effective dose claim 1, wherein the composition is administered over a period of time, prevents development to a patient for the prevention of liver cancer in predisposed patients with liver cirrhosis.
 - 21. Canceled.
 - 22. Canceled.
- 23. (Currently amended) A method of treatment of liver cancer, comprising administering the composition of Claims1-6 claim 1 in combination with other known, standard or experimental treatment protocols for liver cancer.
- 24. (Currently amended) A method of treatment of liver cancer, comprising administering the composition of any of Claims 1-6 as a bridging therapy to down-grade claim 1 to reduce the size of inoperable liver cancers to a resectable or transplantable size.
- 25. (Currently amended) A method of treatment of liver damage caused by chemoembolization, comprising administering the composition of any of Claims 1-6 claim 1 to aide in liver regeneration for normal liver parenchyma damaged in hepatic chemoembolization.
- 26. (Currently ameded) A method for treatment of a disorder of the hepatobiliary system, comprising administering the composition of any of Claims 1-6 claim 1.
 - 27. Canceled.
 - 28. Canceled.
- 29. (Currently amended) A method for the treatment of liver cancer comprising oral administration of the composition in any of Claims 1-6 of claim 1 with other known, standard or experimental treatment protocols.

- 30. Canceled.
- 31. Canceled.
- 32. (New) The pharmaceutical composition of claim 12 comprising, a pharmaceutically acceptable carrier.
- 33. (New) A method of administering of the composition of claim 8, wherein the composition is administered to a patient and the patient has cirrhosis.
- 34. (New) A method of administration of the composition of claim 8, wherein the composition is administered to a patient and the patient has hepatitis.